obesity drugs

Ascletis sees no benefit to high, fast oral GLP-1 dose titration

The latest results show a high starting dose, fast titration model provides the same weight loss and worse tolerability than more measured approaches.

Nick Paul Taylor Apr 23, 2025 7:25am

Pfizer axes oral GLP-1 asset, blowing hole in obesity plan

Apr 14, 2025 7:34am

Novo inks $1B deal for Lexicon’s preclinical obesity prospect

Mar 28, 2025 7:30am

arrow back backwards u-turn turn around reverse

Ascletis slashes funds for former core programs in obesity pivot

Mar 26, 2025 10:00am

MA strategy deal block push come together form

Mira seeks to buy Skny for obesity, smoking cessation asset

Mar 24, 2025 10:08am

Roche pays Zealand $1.6B to codevelop amylin obesity asset

Mar 12, 2025 5:23am